Works matching AU XIAOLIN DONG


Results: 52
    1
    2
    3
    4
    5

    Combination of retagliptin and henagliflozin as add‐on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicentre, randomized, double‐blind, active‐controlled, phase 3 trial.

    Published in:
    Diabetes, Obesity & Metabolism, 2024, v. 26, n. 7, p. 2774, doi. 10.1111/dom.15596
    By:
    • Wang, Yao;
    • Jiang, Chengxia;
    • Dong, Xiaolin;
    • Chen, Mingwei;
    • Gu, Qin;
    • Zhang, Lihui;
    • Fu, Yanqin;
    • Pan, Tianrong;
    • Bi, Yan;
    • Song, Weihong;
    • Xu, Jing;
    • Lu, WeiPing;
    • Sun, Xiaodong;
    • Ye, Zi;
    • Zhang, Danli;
    • Peng, Liang;
    • Lin, Xiang;
    • Dai, Wei;
    • Wang, Quanren;
    • Yang, Wenying
    Publication type:
    Article
    6

    Inside Front Cover.

    Published in:
    Diabetes, Obesity & Metabolism, 2023, v. 25, n. 10, p. C2, doi. 10.1111/dom.15285
    By:
    • Zeng, Jiao'e;
    • Gan, Shenglian;
    • Mi, Nianrong;
    • Liu, Yunfeng;
    • Su, Xiaofei;
    • Zhang, Wenli;
    • Zhang, Juan;
    • Yu, Fang;
    • Dong, Xiaolin;
    • Han, Minmin;
    • Luo, Jianfeng;
    • Zhang, Yi;
    • Chen, Li;
    • Ma, Jianhua
    Publication type:
    Article
    7
    8
    9

    Improved glycaemic control and weight benefit with iGlarLixi versus insulin glargine 100 U/mL in Chinese people with type 2 diabetes advancing their therapy from basal insulin plus oral antihyperglycaemic drugs: Results from the LixiLan‐L‐CN randomized controlled trial

    Published in:
    Diabetes, Obesity & Metabolism, 2022, v. 24, n. 11, p. 2182, doi. 10.1111/dom.14803
    By:
    • Yuan, Xiaoyong;
    • Guo, Xiaohui;
    • Zhang, Junqing;
    • Dong, Xiaolin;
    • Lu, Yibing;
    • Pang, Wuyan;
    • Gu, Shenghong;
    • Niemoeller, Elisabeth;
    • Ping, Lin;
    • Nian, Gaowei;
    • Souhami, Elisabeth
    Publication type:
    Article
    10

    Efficacy and safety benefits of iGlarLixi versus insulin glargine 100 U/mL or lixisenatide in Asian Pacific people with suboptimally controlled type 2 diabetes on oral agents: The LixiLan‐O‐AP randomized controlled trial.

    Published in:
    Diabetes, Obesity & Metabolism, 2022, v. 24, n. 8, p. 1522, doi. 10.1111/dom.14722
    By:
    • Yang, Wenying;
    • Dong, Xiaolin;
    • Li, Qingju;
    • Cheng, Zhifeng;
    • Yuan, Guoyue;
    • Liu, Ming;
    • Xiao, Jianzhong;
    • Gu, Shenghong;
    • Niemoeller, Elisabeth;
    • Chen, Lijuan;
    • Ping, Lin;
    • Souhami, Elisabeth
    Publication type:
    Article
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34

    Molecular Correlates of Diapause in Aphidoletes aphidimyza.

    Published in:
    Insects (2075-4450), 2024, v. 15, n. 5, p. 299, doi. 10.3390/insects15050299
    By:
    • Dai, Xiaoyan;
    • Wang, Yu;
    • Liu, Yan;
    • Wang, Ruijuan;
    • Su, Long;
    • Yin, Zhenjuan;
    • Zhao, Shan;
    • Chen, Hao;
    • Zheng, Li;
    • Dong, Xiaolin;
    • Zhai, Yifan
    Publication type:
    Article
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49
    50